Chicago—Contrast agents used in magnetic resonance imaging (MRI) studies for patients with renal insufficiency are associated with increased mortality in some cases, according to new findings by researchers.
Speaking at the annual Scientific Assembly of the Radiological Society of North America held here in November, Emanuel Kanal, MD, director of Magnetic Resonance Services and a professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, alerted colleagues to the emergence of nephrogenic systemic fibrosis (NSF) and its association with gadolinium-based contrast agents.
Mitka M. MRI Contrast Agents May Pose Risk for Patients With Kidney Disease. JAMA. 2007;297(3):252-253. doi:10.1001/jama.297.3.252